Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

The Eu­ro­pean Med­i­cines Agency has flipped its stance on Ei­sai and Bio­gen’s Alzheimer’s treat­ment Leqem­bi, rec­om­mend­ing au­tho­riza­tion in a nar­row­er pop­u­la­tion than it pre­vi­ous­ly con­sid­ered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER